Results 251 to 260 of about 2,980,265 (315)
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics. [PDF]
Sisler JD +12 more
europepmc +1 more source
Toward Explainable Carcinogenicity Prediction: An Integrated Cheminformatics Approach and Consensus Framework for Possibly Carcinogenic Chemicals. [PDF]
Duy HA, Srisongkram T.
europepmc +1 more source
Naphthalene: MAK Value Documentation, addendum - Translation of the German version from 2022. [PDF]
Hartwig A +1 more
europepmc +1 more source
How to evaluate and select cervical screening and triage tests in vaccinated populations. [PDF]
Wentzensen N, Arbyn M, Poljak M.
europepmc +1 more source
Testing for carcinogenicity of pharmaceuticals.
T, Usui, H, Masuda
openaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Carcinogenicity Testing of Drugs
JAMA: The Journal of the American Medical Association, 1980To the Editor.— I agree with John C. Ballin, MD (242:26, 1979), that the results of studies in which large doses are given to animals for a lifetime do not necessarily mean that "such drugs or chemicals are carcinogenic in man when taken according to label directions." But the studies do not necessarily mean that such drugs or chemicals are not ...
openaire +2 more sources
Carcinogenicity Testing of Drugs
JAMA: The Journal of the American Medical Association, 1979To the Editor.— The National Cancer Institute (NCI) has begun a long-term project of testing commonly used drugs for their possible carcinogenic effect in animals. In conducting these tests, the NCI uses a standard protocol that involves giving drugs for long periods (generally lifetime feeding) in large doses to mice, rats, and other experimental ...
openaire +2 more sources

